(RYTM) – Company Press Releases
-
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
-
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
-
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
-
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
-
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
-
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
-
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
-
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
-
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
-
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
-
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
-
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek®
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®
-
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
-
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Announces Update to September Conference Participation
-
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
-
Rhythm Pharmaceuticals to Present at Investor Conferences in September
-
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
-
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
-
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
-
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
-
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries
-
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Def
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
-
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
-
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
-
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
-
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
-
Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
Back to RYTM Stock Lookup
